Compare Stocks → Trump is sounding the alarm (From Preserve Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:DMACNASDAQ:EFTRNASDAQ:IMVNASDAQ:KZIA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.35+0.7%$1.67$1.08▼$5.50$10.69M0.9914,754 shs2,846 shsDMACDiaMedica Therapeutics$3.65+4.3%$2.77$1.58▼$4.75$138.55M1.7542,044 shs99,948 shsEFTReFFECTOR Therapeutics$2.19+2.8%$8.33$1.60▼$37.00$8.08M0.94308,723 shs43,961 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsKZIAKazia Therapeutics$0.30+7.1%$0.30$0.19▼$1.39$4.90M2.07690,321 shs207,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-1.47%+4.70%-4.96%-49.15%-62.25%DMACDiaMedica Therapeutics+16.67%+35.14%+17.45%+9.03%+110.84%EFTReFFECTOR Therapeutics-3.18%+2.90%-15.14%-79.40%-82.59%IMVIMV0.00%0.00%0.00%0.00%0.00%KZIAKazia Therapeutics+2.98%-21.10%-23.00%+8.78%-77.04%The Sneaky IRS Tax Law that's Sweeping the U.S. (Ad)In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold nowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics1.7699 of 5 stars3.54.00.00.02.50.00.0EFTReFFECTOR Therapeutics1.6076 of 5 stars3.54.00.00.00.00.80.6IMVIMVN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.0091.78% UpsideEFTReFFECTOR Therapeutics3.00Buy$24.00995.89% UpsideIMVIMVN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest DMAC, EFTR, KZIA, IMV, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/28/2024EFTReFFECTOR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AEFTReFFECTOR Therapeutics$3.55M2.28N/AN/A($1.94) per share-1.13IMVIMV$330K0.00N/AN/A($0.69) per share0.00KZIAKazia Therapeutics$20K245.10N/AN/A$0.50 per share0.60Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/AN/ADMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/8/2024 (Confirmed)EFTReFFECTOR Therapeutics-$35.81M-$16.92N/AN/AN/AN/AN/A-160.00%5/14/2024 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AKZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/ALatest DMAC, EFTR, KZIA, IMV, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ADMACDiaMedica Therapeutics-$0.16N/A+$0.16N/AN/AN/A 3/25/2024Q4 2023EFTReFFECTOR Therapeutics-$2.73-$3.42-$0.69-$3.42N/AN/A3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95DMACDiaMedica TherapeuticsN/A19.2719.27EFTReFFECTOR TherapeuticsN/A0.770.77IMVIMVN/A2.932.93KZIAKazia TherapeuticsN/A0.71N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%DMACDiaMedica Therapeutics10.12%EFTReFFECTOR Therapeutics57.67%IMVIMV15.37%KZIAKazia Therapeutics30.89%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%DMACDiaMedica Therapeutics7.20%EFTReFFECTOR Therapeutics8.40%IMVIMV0.33%KZIAKazia Therapeutics1.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics97.92 million3.03 millionNot OptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableEFTReFFECTOR Therapeutics143.69 million3.38 millionOptionableIMVIMV9711.71 million11.67 millionOptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableDMAC, EFTR, KZIA, IMV, and AKTX HeadlinesSourceHeadlineKazia concludes first stage of Phase I advanced cancer treatment trialclinicaltrialsarena.com - May 2 at 9:17 AMKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSprnewswire.com - May 1 at 8:45 AMKazia licenses rare epilepsy drug paxalisib to Korea’s Sovargenbioworld.com - March 23 at 12:04 PMKazia Therapeutics Ltd ADR KZIAmorningstar.com - March 20 at 4:52 PMKZIA Apr 2024 2.500 callfinance.yahoo.com - March 16 at 12:37 AMKazia announces presentation of new data at AACR Annual Meetingprnewswire.com - March 13 at 8:00 AMWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?msn.com - February 21 at 6:59 PMKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointfinanznachrichten.de - February 21 at 1:58 PMKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointfinance.yahoo.com - February 21 at 8:58 AMKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointprnewswire.com - February 21 at 7:30 AMKazia Therapeutics Limitedthestreet.com - February 19 at 6:40 PMKazia Therapeutics Ltd. ADRwsj.com - February 14 at 7:28 PMViking Therapeutics, Inc. Common Stock (VKTX)nasdaq.com - February 13 at 3:25 AMKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSfinance.yahoo.com - January 18 at 9:40 AMKazia Therapeutics files to sell 591,697 ADSs for holdersmsn.com - December 15 at 10:44 PMKazia Therapeutics Announces Closing of $2 Million Registered Direct Offeringfinance.yahoo.com - December 5 at 11:06 PMKazia Therapeutics Shares Tumble on $2 Million Direct Offeringmarketwatch.com - December 1 at 9:29 AMKazia Therapeutics Announces Registered Direct Offering - Quick Factsmarkets.businessinsider.com - December 1 at 9:29 AMKazia Therapeutics Announces $2 Million Registered Direct Offeringfinance.yahoo.com - December 1 at 9:29 AMKazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncologymarkets.businessinsider.com - November 29 at 1:55 PMKazia stock jumps after proposed license deal for paxalisib outside oncologymsn.com - November 29 at 1:55 PMKazia Therapeutics Signs Letter of Intent for Paxalisib Development, Commercializationmarketwatch.com - November 29 at 7:53 AMKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYfinance.yahoo.com - November 29 at 7:53 AMKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGfinance.yahoo.com - November 21 at 8:56 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.eFFECTOR TherapeuticsNASDAQ:EFTReFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.